TitanIvy International

TitanIvy International is a global crossover / pre-IPO fund managed by a team that has collectively achieved exits worth over $20 Billion+. Extensive expertise in steering the operations of publicly traded companies & current and past engagements have involved pivotal roles as Chairman, CEO, and Board Members in notable organizations, including The Bancorp, ApolloMed, Clinigence Holdings, and Cardio Diagnostics among others. Have taken over 20+ companies public delivering 17+ billion in exits, and have successfully closed on 7 de-SPAC transactions, totaling a transaction value of $5 billion+. Co-founded ApolloMed (NASDAQ: AMEH), completed IPO in 2008, raised over $200 million in capital. Peak market cap of $1.4 billion during Warren’s tenure. Private placement investors generated 28x+ their investments. Co-founded Bancorp, led the company through its IPO in 2000. Under our leadership, from 1999 to 2006, the stock price surged from $9.50 to $28.50, a return of 200%+ . Our seasoned team boasts decades of experience successfully operating both public and private enterprises, We possess exclusive deal flow in a fiercely competitive environment. Pre-IPO Private Equity Selectively invest in pre-IPO and IPO headed growth equity rounds of companies in our network Crossover Investments TitanIvy boasts expertise in diverse exit strategies, including IPOs, reverse mergers, and direct listings across global exchanges SPAC Sponsoring Significant expertise Investing in TitanIvy-backed SPACs, IPOs, and other alternative public vehicles Public Company Turnarounds Expertise taking controlled position and orchestrating company turnarounds. Distressed Public Equities Allocate capital towards operationally sound “toxic debt” & distressed publicly traded companies Invest in IPOs Take positions in PIPEs, convertible securities, Last-in/First-out positions and common stocks of companies at the time of the IPO or de-SPAC